[go: up one dir, main page]

RU2004116313A - Альфа-форма или бета-форма кристалла производного ацетанилида - Google Patents

Альфа-форма или бета-форма кристалла производного ацетанилида Download PDF

Info

Publication number
RU2004116313A
RU2004116313A RU2004116313/04A RU2004116313A RU2004116313A RU 2004116313 A RU2004116313 A RU 2004116313A RU 2004116313/04 A RU2004116313/04 A RU 2004116313/04A RU 2004116313 A RU2004116313 A RU 2004116313A RU 2004116313 A RU2004116313 A RU 2004116313A
Authority
RU
Russia
Prior art keywords
crystal
aminothiazol
phenylethyl
hydroxy
ethyl
Prior art date
Application number
RU2004116313/04A
Other languages
English (en)
Other versions
RU2303033C2 (ru
Inventor
Соуитироу КАВАЗОЕ (JP)
Соуитироу Кавазое
Кенитироу САКАМОТО (JP)
Кенитироу САКАМОТО
Юдзи АВАМУРА (JP)
Юдзи АВАМУРА
Тацу МАРУЯМА (JP)
Тацуя Маруяма
Такаюки СУЗУКИ (JP)
Такаюки Сузуки
Кенити ОНДА (JP)
Кенити Онда
Тосиюки ТАКАСУ (JP)
Тосиюки ТАКАСУ
Original Assignee
Яманоути Фармасьютикал Ко.,Лтд (Jp)
Яманоути Фармасьютикал Ко.,Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19148268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2004116313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Яманоути Фармасьютикал Ко.,Лтд (Jp), Яманоути Фармасьютикал Ко.,Лтд filed Critical Яманоути Фармасьютикал Ко.,Лтд (Jp)
Publication of RU2004116313A publication Critical patent/RU2004116313A/ru
Application granted granted Critical
Publication of RU2303033C2 publication Critical patent/RU2303033C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Claims (12)

1. б-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида.
2. б-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида, имеющая пик теплопоглощения при 142-146°С при ДСК анализе.
3. б-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида, имеющая основные пики порошковой дифракции рентгеновских лучей вблизи 5,32, 8,08, 15,28, 17,88, 19,04, 20,20, 23,16 и 24,34 в единицах 2(°).
4. б-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида, имеющая пик теплопоглощения при 142-146°С при ДСК анализе и имеющая основные пики порошковой дифракции рентгеновских лучей вблизи 5,32, 8,08, 15,28, 17,88, 19,04, 20,20, 23,16 и 24,34 в единицах 2и(°).
5.Фармацевтическая композиция, включающая -форму кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида по пункту 1 и фармацевтически приемлемый носитель.
6. Противодиабетическое лекарственное средство, включающее -форму кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида по пункту 1 и фармацевтически приемлемый носитель.
7. в-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида.
8. в-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида, имеющая пики теплопоглощения при 90-110°С и при 142-146° при ДСК анализе.
9. в-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида, имеющая основные пики порошковой дифракции рентгеновских лучей вблизи 9,68, 19,76, 20,72, 22,10 и 23,52 в единицах 2и(°).
10. в-форма кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида, имеющая пики теплопоглощения при 90-110°С и при 142-146° при ДСК анализе и имеющая основные пики порошковой дифракции рентгеновских лучей вблизи 9,68, 19,76, 20,72, 22,10 и 23,52 в единицах 2и(°).
11.Фармацевтическая композиция, включающая -форму кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида по пункту 7 и фармацевтически приемлемый носитель.
12. Противодиабетическое лекарственное средство, включающее в-форму кристалла (R)-2-(2-аминотиазол-4-ил)-4’-[2-[(2-гидрокси-2-фенилэтил)амино]этил]ацетанилида по пункту 7 и фармацевтически приемлемый носитель.
RU2004116313/04A 2001-10-30 2002-10-29 Альфа-форма или бета-форма кристалла производного ацетанилида RU2303033C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-332914 2001-10-30
JP2001332914 2001-10-30

Publications (2)

Publication Number Publication Date
RU2004116313A true RU2004116313A (ru) 2005-03-27
RU2303033C2 RU2303033C2 (ru) 2007-07-20

Family

ID=19148268

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004116313/04A RU2303033C2 (ru) 2001-10-30 2002-10-29 Альфа-форма или бета-форма кристалла производного ацетанилида

Country Status (17)

Country Link
US (2) US7342117B2 (ru)
EP (3) EP1932838A3 (ru)
JP (1) JP3800220B2 (ru)
KR (1) KR100908796B1 (ru)
CN (1) CN1243740C (ru)
AU (1) AU2002344419C1 (ru)
BR (1) BRPI0213570B8 (ru)
CA (1) CA2464068C (ru)
ES (1) ES2404071T3 (ru)
HU (1) HU230481B1 (ru)
MX (1) MXPA04003936A (ru)
NO (1) NO326965B1 (ru)
PL (1) PL218982B1 (ru)
RU (1) RU2303033C2 (ru)
TW (1) TW200300020A (ru)
WO (1) WO2003037881A1 (ru)
ZA (1) ZA200403044B (ru)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TR201802207T4 (tr) * 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
JP5782438B2 (ja) * 2010-06-16 2015-09-24 武田薬品工業株式会社 アミド化合物の結晶
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (ru) * 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
JPWO2013147134A1 (ja) 2012-03-30 2015-12-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
CN103387500A (zh) * 2012-05-11 2013-11-13 上海医药工业研究院 一种米拉贝隆及其中间体的制备方法
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103641792B (zh) * 2013-12-27 2015-07-22 国药集团国瑞药业有限公司 一种米拉贝隆有关物质或其盐、其制备方法和用途
CN104876889B (zh) * 2014-02-27 2017-02-22 人福医药集团股份公司 化合物的合成方法
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
CN103896872A (zh) * 2014-04-29 2014-07-02 黑龙江大学 米拉贝隆的合成方法
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
WO2016020440A1 (en) * 2014-08-06 2016-02-11 Interquim, S.A. Method for the synthesis of mirabegron and its derivatives
WO2016024284A2 (en) 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN105481705A (zh) * 2014-08-23 2016-04-13 南京海纳医药科技有限公司 (r)-2-[[2-(4-氨基苯基)乙基]氨基]-1-苯乙醇的制备及应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
EP3197449B1 (en) * 2014-09-26 2018-11-21 Universita' Degli Studi di Bari Selective agonists of beta-adrenergic type 3 receptors (bar3) for the treatment of nephrogenic diabetes insipidus
CA2962664A1 (en) * 2014-10-01 2016-04-07 Apotex Inc. Solid forms of mirabegron
US9981927B2 (en) 2015-02-02 2018-05-29 Lupin Limited Process for preparation of polymorphic form of Mirabegron
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
FR3043555B1 (fr) 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) Mirabegron pour le traitement de maladies retiniennes
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
CN105801438A (zh) * 2016-04-12 2016-07-27 济南大学 一种米拉贝隆中间体的合成方法
CN107963976A (zh) * 2016-10-20 2018-04-27 中国动物疫病预防控制中心 一种苯乙醇胺类化合物中间体的制备方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
CN108658797A (zh) * 2018-06-19 2018-10-16 安徽德信佳生物医药有限公司 一种米拉贝隆中间体(r)-2-(4-硝基苯乙基氨基)-1-苯基乙醇盐酸盐的合成
CN108947853A (zh) * 2018-06-29 2018-12-07 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成米拉贝隆中间体的方法
KR101928987B1 (ko) * 2018-08-28 2018-12-13 (주) 성운파마코피아 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
NZ774649A (en) 2018-12-05 2025-07-25 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
CN110590699B (zh) * 2019-09-29 2022-11-15 广东先强药业有限公司 一种米拉贝隆的精制方法
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
CN114539182B (zh) * 2020-11-24 2024-08-09 威智医药股份有限公司 转晶溶剂及其应用和米拉贝隆α晶型的制备方法
CN114539084B (zh) * 2020-11-24 2024-04-02 威智医药股份有限公司 米拉贝隆及其中间体的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
CN112574137A (zh) * 2021-01-19 2021-03-30 南京美瑞制药有限公司 一种α晶型米拉贝隆的制备方法
KR20240116208A (ko) 2023-01-20 2024-07-29 이니스트에스티 주식회사 결정형의 미라베그론 신규염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1921577B2 (de) * 1969-04-28 1972-04-06 Nixdorf Computer Ag, 4790 Paderborn Trommelartige vorrichtung zn buchungs- und schreibautomaten mit greifeinrichtung zum erfassen und einziehen von kontokarten o dgl
JPH02279685A (ja) 1989-04-18 1990-11-15 Yoshitomi Pharmaceut Ind Ltd 新規な結晶構造を有するチアジアジン化合物およびその製造法
BR9807506A (pt) * 1997-01-23 2000-03-21 Yamanouchi Pharma Co Ltd Derivados de amida e composições medicinais dos mesmos
DK1028111T3 (da) * 1997-10-17 2004-09-20 Yamanouchi Pharma Co Ltd Amidderivater eller salte heraf
JP3901832B2 (ja) 1998-03-13 2007-04-04 大日本インキ化学工業株式会社 キノリノン誘導体製剤、及びその製造法
JP2000212168A (ja) 1999-01-22 2000-08-02 Yamanouchi Pharmaceut Co Ltd ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶
CA2349663C (en) * 1999-09-10 2006-10-31 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative

Also Published As

Publication number Publication date
TW200300020A (en) 2003-05-01
EP2298752A1 (en) 2011-03-23
HUP0401665A1 (hu) 2004-11-29
KR20050040837A (ko) 2005-05-03
AU2002344419C1 (en) 2024-02-01
MXPA04003936A (es) 2004-06-18
RU2303033C2 (ru) 2007-07-20
JPWO2003037881A1 (ja) 2005-02-17
EP1932838A2 (en) 2008-06-18
US7982049B2 (en) 2011-07-19
EP2298752B1 (en) 2013-03-27
ZA200403044B (en) 2005-06-29
AU2002344419B2 (en) 2007-12-13
EP1440969A4 (en) 2005-01-19
US7342117B2 (en) 2008-03-11
KR100908796B1 (ko) 2009-07-22
EP1440969A1 (en) 2004-07-28
CA2464068A1 (en) 2003-05-08
EP1932838A3 (en) 2008-07-30
BRPI0213570B1 (pt) 2018-02-27
CA2464068C (en) 2007-10-16
CN1243740C (zh) 2006-03-01
HUP0401665A3 (en) 2008-05-28
US20050004190A1 (en) 2005-01-06
TWI322805B (ru) 2010-04-01
HU230481B1 (hu) 2016-07-28
NO20042227L (no) 2004-05-28
BR0213570A (pt) 2004-10-26
BRPI0213570B8 (pt) 2021-05-25
KR100908796B9 (ko) 2024-07-17
PL369874A1 (en) 2005-05-02
US20080214633A1 (en) 2008-09-04
PL218982B1 (pl) 2015-02-27
CN1575287A (zh) 2005-02-02
WO2003037881A1 (en) 2003-05-08
NO326965B1 (no) 2009-03-23
ES2404071T3 (es) 2013-05-23
JP3800220B2 (ja) 2006-07-26

Similar Documents

Publication Publication Date Title
RU2004116313A (ru) Альфа-форма или бета-форма кристалла производного ацетанилида
HUP0400932A3 (en) Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
HUT77285A (hu) Vírusellenes hatású benzimidazolszármazékok és e vegyületeket tartalmazó gyógyászati készítmények, valamint eljárás e vegyületek előállítására és közbenső termékeik
IL126674A (en) Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
DE59009074D1 (de) Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus.
ZA95814B (en) Medical treatment
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
NO912607L (no) Fast, oral, farmasoeytisk doseringsform med programmert frigivning
DE3650315D1 (de) Cyancrotonsäureamidverbindung als Arzneimittel mit immunmodulierenden Eigenschaften.
ATE84413T1 (de) Arzneimittel, enthaltend di-tert.butylhydroxyphenyl-derivatesowie neue derivate.
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
DK0502788T3 (da) Trisubstituerede triaziner og pyrimidiner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
JP2005509503A5 (ru)
SI0861250T1 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
CL2003001692A1 (es) Uso de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida en la elaboracion de un medicamento para el tratamiento del cancer en un animal de sangre caliente.
RU2001116105A (ru) Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h-бензимидазол-5- карбоксамида
DK0571511T3 (da) Nye urea- og thioureaforbindelser, deres fremstilling og terapeutiske anvendelse
AU7008900A (en) N-substituted norephedrine chiral derivatives, their preparation and their use for the synthesis of optically active functionalised compounds by hydrogen transfer
ZA882854B (en) Substituted quinoxalyl-imidazolidine-2,4-diones,processes for their preparation,their use as medicaments and pharmaceutical preparations
ES2189163T3 (es) Nitro-benzamidas utiles como agentes anti-arritmicos.
SE9901901D0 (sv) Compounds
IT9020943A0 (it) Composizione farmaceutica per uso orale a rilascio modificato di antiinfiammatori non steroidei
ES515068A0 (es) "procedimiento para la preparacion de n-(2-(((5-dimetilamino)-metil-2-furanil)-metil)-tio)-etil)-n'-(3,4-metilendioxibencil)-2-nitro-1,1-etendiamina".
DK0488044T3 (da) En imidazobenzodiazepin til behandling af søvnforstyrrelser
JPS5573610A (en) Amphiblocking drug for alpha and beta receptors

Legal Events

Date Code Title Description
RZ4A Other changes in the information about an invention